AVXL Valuation

Anavex Life Sciences Corp

Add to Watchlist

Advanced Chart

8.740

+0.28(3.310%)1D

Overview
Forecast
Valuation
Earnings

AVXL Relative Valuation

AVXL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AVXL is overvalued; if below, it's undervalued.

Historical Valuation

Anavex Life Sciences Corp (AVXL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.45. The fair price of Anavex Life Sciences Corp (AVXL) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：8.74

Fair

-18.02

Trailing

Forward

0.00

EV/EBITDA

Anavex Life Sciences Corp. (AVXL) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -4.51. The thresholds are as follows: Strongly Undervalued below -18.77, Undervalued between -18.77 and -11.64, Fairly Valued between 2.62 and -11.64, Overvalued between 2.62 and 9.76, and Strongly Overvalued above 9.76. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

6.37

EV/EBIT

Anavex Life Sciences Corp. (AVXL) has a current EV/EBIT of 6.37. The 5-year average EV/EBIT is -12.28. The thresholds are as follows: Strongly Undervalued below -39.99, Undervalued between -39.99 and -26.13, Fairly Valued between 1.57 and -26.13, Overvalued between 1.57 and 15.42, and Strongly Overvalued above 15.42. The current Forward EV/EBIT of 6.37 falls within the Overvalued range.

0.00

Anavex Life Sciences Corp. (AVXL) has a current PS of 0.00. The 5-year average PS is 145.97. The thresholds are as follows: Strongly Undervalued below -686.39, Undervalued between -686.39 and -270.21, Fairly Valued between 562.15 and -270.21, Overvalued between 562.15 and 978.32, and Strongly Overvalued above 978.32. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Anavex Life Sciences Corp. (AVXL) has a current P/OCF of 0.00. The 5-year average P/OCF is -11.09. The thresholds are as follows: Strongly Undervalued below -34.93, Undervalued between -34.93 and -23.01, Fairly Valued between 0.83 and -23.01, Overvalued between 0.83 and 12.75, and Strongly Overvalued above 12.75. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Anavex Life Sciences Corp. (AVXL) has a current P/FCF of 0.00. The 5-year average P/FCF is -8.12. The thresholds are as follows: Strongly Undervalued below -26.44, Undervalued between -26.44 and -17.28, Fairly Valued between 1.04 and -17.28, Overvalued between 1.04 and 10.20, and Strongly Overvalued above 10.20. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Anavex Life Sciences Corp (AVXL) has a current Price-to-Book (P/B) ratio of 8.21. Compared to its 3-year average P/B ratio of 5.22 , the current P/B ratio is approximately 57.10% higher. Relative to its 5-year average P/B ratio of 7.02, the current P/B ratio is about 16.88% higher. Anavex Life Sciences Corp (AVXL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.92%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.34% , the current FCF yield is about -100.00% lower.

8.21

P/B

Median3y

5.22

Median5y

7.02

-5.11

FCF Yield

Median3y

-4.92

Median5y

-4.34

Competitors Valuation Multiple

The average P/S ratio for AVXL's competitors is 1.80, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AVXL.O

Anavex Life Sciences Corp

Vir Biotechnology Inc

Iovance Biotherapeutics Inc

Performance Decomposition

Market capitalization of AVXL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AVXL in the past 1 year is driven by Unknown.